Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 21,250,000 shares, a drop of 7.6% from the June 30th total of 23,000,000 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average daily volume of 7,530,000 shares, the short-interest ratio is presently 2.8 days.
Wall Street Analyst Weigh In
GILD has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Oppenheimer reissued an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a report on Monday, July 8th. Cantor Fitzgerald decreased their target price on Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Monday, July 22nd. Finally, UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Twelve equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $81.81.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Trading Up 1.0 %
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Global Retirement Partners LLC lifted its holdings in Gilead Sciences by 41.9% during the fourth quarter. Global Retirement Partners LLC now owns 6,744 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 1,991 shares during the period. Chicago Capital LLC lifted its holdings in Gilead Sciences by 7.0% during the fourth quarter. Chicago Capital LLC now owns 4,594 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 300 shares during the period. Silverlake Wealth Management LLC purchased a new stake in Gilead Sciences during the fourth quarter worth $209,000. Essex Savings Bank lifted its holdings in Gilead Sciences by 5.6% during the fourth quarter. Essex Savings Bank now owns 4,547 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 240 shares during the period. Finally, Stonegate Investment Group LLC lifted its holdings in Gilead Sciences by 6.7% during the fourth quarter. Stonegate Investment Group LLC now owns 7,297 shares of the biopharmaceutical company’s stock worth $591,000 after buying an additional 460 shares during the period. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- First Solar Stock: The Dawn of a New Rally in Share Prices
- Which Wall Street Analysts are the Most Accurate?
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- What Are the FAANG Stocks and Are They Good Investments?
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.